With the addition of this newly issued patent in BrazilECD is now covered by 20 granted patents in major global markets with patents now granted in: United States, Australia, Belgium, Brazil, Canada, China (People’s Republic), Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Japan, Mexico, Netherlands, Spain, Sweden and the UK.
Tooth decay is the most common chronic disease in the world and affects approximately 2.3 billion people worldwide. The majority of cavities occur in the posterior teeth (molars and premolars). Without using radiation, the ECD painlessly measures the electrical conductance of enamel at these vulnerable sites and can detect early signs of tooth decay immediately that X-rays
often missing. ECD is FDA cleared and used by hundreds of dentists in the United States
“This is another important step for Ortek as we expand the international patent portfolio for ECD,” said Ortek’s President. Mitchell Goldberg. “Early detection of any disease is critically important, and ECD enables dental professionals to detect tooth decay at a very early stage, helping patients avoid the pain, damage and costs associated with dental caries. more advanced caries.”
Revolutionary ECD technology was developed and tested at Stony Brook University School of Dentistry. Ortek has entered into an exclusive worldwide license to the ECD patents with The Research Foundation for The State University of New York.
Ortek Therapeutics, Inc. is a global leader in the development and commercialization of advanced oral care technologies. For more information about the company, visit ortekinc.com.
SOURCE Ortek Therapeutics, Inc.